PFIZER INC. (LON:PFZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

PFIZER INC. (LON:PFZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 13, 2017, Pfizer Inc. (the "Company") announced that Albert Bourla, 56, currently Group President, Pfizer Innovative Health, has been appointed Chief Operating Officer of the Company effective January 1, 2018. The Company also announced that effective January 1, 2018, John D. Young, 53, currently Group President, Pfizer Essential Health, has been appointed Group President, Pfizer Innovative Health and Angela Hwang, 52, currently Global President and General Manager for Pfizer Inflammation & Immunology, has been appointed Group President, Pfizer Essential Health. Any related changes in compensation arrangements required to be disclosed on Form 8-K will be so disclosed promptly following approval by the Compensation Committee of the Board of Directors.

The related press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit Number

Exhibit Description

Press Release of Pfizer Inc. dated November 13, 2017


PFIZER INC Exhibit
EX-99.1 2 pfe_11132018exh991.htm EXHIBIT 99.1 PFIZER INC. PRESS RELEASE Exhibit Exhibit 99.1 For immediate release:Media Contact:November 13,…
To view the full exhibit click here